» . . , » (03.03.03. – ) : , 2012 . ...................................... 4 ..................................................................................................... 6 1. , . ( ) ............................................................................................12 1.1 . - ........................................12 1.2 , ....................................................15 , 1.3 .....19 1.4 ......................26 1.5 ............................39 , ..................43 2. 2.1 .................................45 2.2 ...........................................46 2.3 .....................................52 ........57 3. 3.1 .................................................................................57 2 3.3 ............................................................................................................61 3.4 .............................63 3.5 ............................................................................................................78 ...........................93 3.6 4. ..........................................................................95 .....................................................................................................107 .........................................................................108 3 – – – – – – – – – – – – – – – – APC - antigen-presenting cell GNLY – granulysin HPV - human papillomavirus HSV – herpes simplex virus IFN - interferon IL – interleukin LIF - leukemia inhibitory factor MHC - major histocompatibility complex PAMP - pathogen-associated molecular patterns PRR - pattern recognition receptor TGF - transforming growth factor Th – T-helper 4 TLR – toll-like receptor TNF - tumor necrosis factor 5 . , - ( ) – , , , [30; 33; 73]. , [8]. , : ( , , -, ) . . , ( ), [8; 11]. , , , . 6 , . , - . , [14; 169]. , . [90; 122]. . , 2- 4- ) : ( , , , , . - , , . 7 - . 1. . 2. ( ) (IL1B, IL6, IL8, IL10, IL12A, IL15, IL18, IL23, TNF , IFNG, TGFB1 (TBX21, GATA3, FOXP3 LIF), RORC), Toll- (TLR2, TLR4, TLR9), (CD45, CD68, CD69, IL2R ) (GNLY) . 3. . 4. . 5. . 8 6. , . (IL1 , IL6, IL8, IL10, IL12A, IL15, IL18, IL23, IL2RA, GNLY, TNFA, TGFB1, LIF, IFNG, TLR2, TLR4, TLR9, TBX21, GATA3, RORC, FOXP3, CD45, CD68, CD69) . 14 (IL1B, IL8, IL10, D45, CD69, TLR2, TLR4, TNF , GATA3, CD68, IL12A, IL18, TGFB1, RORC) 24 . IL12A IL18, CD68 Th2- GATA3 , . , , IL1B, IL18, IL10, TLR4, CD68 GATA3 . . IL1B, IL8, IL10, TNFA, TLR2, 9 TLR4, CD45, CD69, GATA3, CD68, TGFB1, IL12A, RORC, IL18 . IL1B, IL18, IL10, CD68, TLR4 GATA3 96% 95% , . . . : , , . , , , , . , . 201147924 « 10 ». 7 , 5 , . « »( « , 2011 .), VI »( , 2012 .), V " . "( , 2012 .). 16.522.12.2009 29 2011 . 128 , , , , , , , 74 123 . 11 11 24 . 1. , . ( ) 1.1 . - . - [34; 52]. : , . , , , [41; 62]. , , : 28 60% [35]. [33; 48; 49; 73; 75; 88; 167]. ( 12 ), ( ) ( ) [4; 22; 52], . , , [4]. . , , , , , , . IUSTI (International Union against Sexually Transmitted Infections) 2011 [170] : (22-50% ), (17-39%) (4-35%), , . . Anderson M.R. 30% [80]. IUSTI, , , , [3; 13; 30; 34; 37; 45; 46; 58; 66]. 13 , , . , , , ) [8; 10; 11]. , , . , , , . , , . . . , , , . , , ( ). , . : ( , ), ), . 14 . , , , , , . 1.2 , , . , , , . , , , . , , : 3,8—4,5, . 108-109 1 – 105-108, , 95-98% – 106-109 . 15 – 103-105 . 400 150 [45]. , ), , ( ), [45; 60]. , , , . , [1; 126]. , , , . . ( ), - . , . , (3,8—4,5). , . , 16 . , , . , . III [64]. , . . (Lactobacillus), : L. acidophilus, L. jensenii, L. casei, L. gasseri, L. crispatus, L. plantarum, L. fermentum, L. cellobiosus, L. brevis L. Salivarius. : , , L. crispatus, L. jensenii, L. gasseri L. iners [104; 123; 142; 150; 162; 190; 196]. , – , [1; 193]. , , 46,5 , , , , . , 17 100%. . , . . [2] 5% , 37% – 61% – . , . 2 2 [7; 15; 45; 61; 65]: : ; ; ; . , . . 30 [28; 123]. , , , , , , , , ., 18 Candida. 15-20% [3; 104; 117; 193]. , - 400 . [10; 72; 142; 193] , . Atopobium spp., Megasphaera spp. Leptotrichia spp., , Lactobacillus, , . , , , . , , . Atopobium vaginae [169]. . , , [193; 195; 196]. 1.3 , . 19 , , ( , , , , .), ( , — , , , , , ; ; ( , , ); ; , .) [59]. , ( , ) [34; 55; 73]. , , . . — , . — , , ( ). — 20 , , , ). , , ). [16; 60]. ( ) . 5–60% . . , . , : , , , , , [37]. . (Gardnerella vaginalis, Mobiluncus spp., Bacteroides spp., Fusobacterium spp., Prevotella spp., Prophyromanas spp., Peptostreptococcus spp. Atopobium vaginae .) [115; 147; 159; 186]. , , 21 108-109 [13]. - 4,5, . , ( ), , , . , , . , « « » » [4; 16]. , [66]. , Amsel R. (1983 .). : , ; ; >4,5; " " [36; 114; 151; 159]. . , , Enterobacteriaceae (Escherichia coli, Klebsiella 22 spp.), Staphylococcus aureus, S. epidermidis, Streptococcus agalactiae, Enterococcus spp. (103-104 . , ) . . , « » , . [3; 22; 108; 138; 177]. , , Candida. , , — 10 79%, ( , , ) [19; 38; 63; 113; 170]. Candida spp. 104 . C.ablicans. , , , Candida spp. , [3; 4; 51]. . , 6,0-6,5, ( 2,5-3,0), . , . C.albicans . , . 23 C. albicans, — C. Glabrata [35; 39; 45; 161]. 3 : , , 104 ( ). Candida 15–30% - 40%). ( - ), , . , , [4; 67; 68; 70; 197]. 40% - . Ureaplasma spp. 50% ( - Mycoplasma hominis , 10% , Ureaplasma spp. 80%). Mycoplasma hominis , , . [24; 31; 57; 92; 139; 153; 187]. , . , . , 24 [18]. ) , [5] -, , , . [56]. , , . , [54]. , - , , , [8; 11; 30]. , , , , , , . : 3–4 25 , , [4; 9; 12; 31; 43; 47; 71; 147; 164; 177; 187]. 1.4 , . , , , , , . , . – , . . , , . , . , , . , , 26 . , , , , – [40]. - , . , , . , , , [47]. , : . . , , , . [7; 149]. – 27 . , . , . , , (lamina propria). : , , , , , , , ( 1). , , [160; 173]. . 1. : ( ) ( 28 ). ( ( ) ), . , CD8+ , , , . . , ( , , ( ), ). IgA+ , . . , , [74; 158]. . , , . – , . [42]. , . . , , , , , . , , , ( .). 29 , , , , , , [7; 29; 84; 100; 124; 182]. . , , . 2 2 , . , . , , « . » , , IgA [178], , , , , [91]. . . , [122; 172], – , [74; 93]. . , , . (TNF , IL-1 , IL-6, IL-8 .), . 30 , , ( , - 2) [128]. . (APC). . APC, [96; 119; 134; 154] . 2. . ( , , , .) - (pattern-recognition receptor – PRR ), [125; 129; 131; 155]. 31 . ( - - pathogen-associated molecular pattern – PAMP ). PAMP , ( , , , , , , , .), ( , , ), , , « , » [78]. PRR PAMP, , , [129; 184]. PRR, (TLR – toll-like receptor), RIGreceptor), NOD- (RLR – RNA-like (NLRs - Nucleotide Oligomerization Domain-like receptor), , , [99]. TLR . TLR. 10 , -TLR1, -2, -4, -5 , TLR3, -7, -8 , ( 3) [83; 94]. 32 -6 -9, TLRs , . , TLR2 - TLR1 TLR6 . . . 3. TLR . TLRs c , . MyD88 ( 88), NF-kB, (TNFa TLR3 TLR4 IL-6) . MyD88- , 3 (IRF-3). 33 I ( 4) [137; 143; 152; 192]. Kaei Nasu [152] TLRs, TLR1 , TLR10. TLR2 , , . TLR4 , (IL-1 , IL-8, TNF ). TLR9 CpG- . [152; 190]. . 4. TLRs ( ) [114; 116; 149] TLR2, -4, -6, (IL-1 , IL-6, IL-8, TNF ) . 34 , PAMP [181] , , (antigen- presenting cell – APC ), , MHC II (major histocompatibility complex class II– CD4+ ) 2 CD8+ . , . [101]. PAMP, , . TGF , , IL-10 – , . D4+ . . – Th1 2 Th2 (Th – T-helper). Th1- TBX21) IL-2, TNFA, TNFB IFNG, , , , Th2- GATA3) 4, IL-5, IL-10 IL-6, IL- ., , ( ). , IL-4 Th1- Th2- (IFNG ) . 35 , IFNG Th1- – Th2- , , IL4 . , Th1- IL-12, IL-23 IFNG, IL18, IL-27. , TNFA, TNFB IFNA. Th2- IL-4 Th2- IL-13, IL-10, IL-6, IL-2, IL-19 p40 IL-12. [140; 172] , . [79; 81; 85; 90; 114; 121; 151] IL-1A, IL-1B, IL-6, IL-8, TNFA , , , , Neisseria gonorrhoeae, Chlamydia trachomatis. IL-12 IFNG , Th1[79; 164] [81; 90; 179]. IL-10 , . . [79; 85; 149; 164]. , 36 [44; 65; 104], . CD4+-T, : ( ) . CD8+ FoxP3, , - TGFB, IL-10 , . , , . , T CD8+ . [6; 20; 74; 130; 166]. CD4+ lamina pripria . CD8+ ) ( , , [158]. , , . . T- , T, IFNG, TNFA IL-17. , . , [36; 74]. 37 , – IgM- , . . IgA. IgA , . . . [9] [46] . . , IgA, IgG IgM . . [17] . IgA . . [23] , , A, M, G, , . , . , . . (IL1B, IL18, IL12A, TNFA, IL23), IL10, IL15), (IL6) TLR (TLR2, -4, -9), , Th1- (GATA3), Th17- (RORC), , 38 (TGFB, (FOXP3), (TBX21), Th2- (CD45 – , CD68 – , CD69 – , IL2RA – ), (GNLY), . 1.5 , : , . . . , , , , , . [14; 169]. » , , . : , , , , ) ( [8; 10]. 39 7 ( ., .) . . [2; 4] : , ( , , ( ( . , ), ), )( ). [21] , 4 : 1. , , , , « » . . 2. – , , . ( 10), . , , , , . 3. , , , « ». , . . 40 4. ( ) – ( 10), , , . [88; 151; 171], . . 16S , , , [8; 11; 72; 76; 97; 162; 185]. , . . . , . , , , - [25; 112; 120; 188]. , 41 , . , , . , . , , . 42 2. 295 . , . » 16.522.12.2009. 194 19 18 45 40 101 37 41 . . 3-5- . , , ( ). , , , ( 10 ). (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium) 1 2 , , . , . 43 « » . « »( , 2009/04663) . . (2011). (n=194) : (n=40), (n=115); 10 : (n=14), 103 ( Candida spp. ) , 104 Ureaplasma spp. (n=10) (n=15). (n=101) : (n=42), (n=24); 10 : Candida spp. (n=11), 103 , 104 Ureaplasma spp. (n=8). (n=16) , ( ) , . . 44 : 1. , , . 2. . : 1. . 2. . 2.1. , . 2.2. « ». 2.3. . 3. . 2.1 : , , . , , , , , , , , . , , , . , , 45 . 2.2 . . . : – , , , « » ( , , ), ), , , , ), , , . [2; 4]. , ; – ; ; – , , . , , 46 « »; , , ( , ); – , ; ; . 3 Candida . 1. (Candida ) , ; (10-15 ) (30-50 ); ; , , . 2. , « »; ; – , ; , / ; . 3. ; 47 , ; ; , . , ; ( 10 ); ; ; – (+) . ( ) , « » ; 10 ; ; . « ». ( ) . 13000 10 100 . « », . ). 48 » (« - , , . 100 . (« , », ) ( )), Lactobacillus spp. 14 , (Enterobacterium spp., Streptococcus spp., Staphylococcus spp)., (Gardnerella bivia/Porphyromonas spp., Eubacterium spp., vaginalis/Prevotella Sneathia spp./Leptotrihia spp./Fusobacterium spp., Megasphaera spp./Veillonella spp./Dialister spp., Lachnobacterium spp./Clostridium spp., Mobiluncus spp./Corynebacterium spp., Peptostreptococcus spp., Atopobium vaginae), Mycoplasma hominis, Ureaplasma spp. Candida spp. : Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis , (HSV-1, HSV -2, CMV) ). 35 :1 – 94º 30 94º , 64º 15 « – 80º 30 ; 45 , 94º 1 – 94º 10 -964» (« », 30 ;5 , 10º – ). 64º FAM, HEX ROX. . « » , [11], » ». . 49 . . , , . , . 104 , 104 , . , . ( ). - , , . . 106 – 108 , – 105 – 107 – . , , , , . . Lactobacillus ( ). , 106–108 , – 105 – 107 – 50 . -, -, Candida. , Candida, . , Ureaplasma spp 104 Mycoplasma hominis . Candida spp 103 « » Candida spp. : 1. – , : Gardnerella vaginalis /Prevotella bivia/Porphyromonas spp; Atopobium vaginae; Eubacterium spp; Sneathia spp /Leptotrihia spp/Fusobacterium spp; Megasphera spp/Veilonella spp/Dialister spp; Lachnobacterium spp/Clostridium spp; Mobiluncus spp/Corynebacterium spp; Peptostreptococcus spp. 2. – , : Enterobacteraceae, Streptococcus spp 3. - Staphylococcus spp. , , Candida. . (IL1B, IL6, IL8, IL10, IL12A, IL15, IL18, IL23, TNF , IFNG, TGFB1, LIF), (TBX21, GATA3, FOXP3, RORC), Toll(TLR2, TLR4, TLR9), CD69, IL2RA) (CD45, CD68, (GNLY) 51 . ( », « », « ). , . 50 . 40 33 ( ). . 40º 30 , 95º 5 . 5 . . . TBP, B2M, GUSB. 3 , 600 1 10 180 . 15 36 ( p), 10-50 108 . (« », ). . . 2.3 . «SPSS Statistics 17.0 for Windows». 52 - . . , — (25- ), 75- . , (Cp) . ( Cq) 3 . 3 (NF) – Cp ( = ( )+ Expression(x) = 2 ( ( 2 )+ ( ) ) ( . )) x : . . , . « « » (box-and-whisker plot). » 1 . 3 (x25, x75) – . (x1, x2), : = max( = min , , 1,5 ( + 1,5 ( )), ) . 53 « » ( . 5. 5 ). . , . . ) . . <0,05. .) % . ( 2). <0,05. (OR), 95% 54 . p<0,05. , , . ( ), . = + + + , m=1,…, n, k=1,…,g ( . - m x ) k; m– k. , . «SPSS Statistics 17.0 for Windows». , . . cut off) ROC- (Receiver Operator Characteristic) . ROC- , . 55 (AUC - Area Under Curve) 1). 1. AUC AUC 0,9-1,0 0,8-0,9 0,7-0,8 0,6-0,7 0,6 cut off . . . 56 3. 3.1 . 194 128 (66,0%), - 62 (48,4%), – 66 (51,6%). (n=62) 6%, 94%, (104 Candida spp. 103 ) . 66 28 104 Ureaplasma spp. , 103 Candida spp. (43,5%) 56 (84,8%) , 18 (28,1%) . 20% . 80%. 66 (34,0%) 194 , 75% . 1% 94% 8 (12,1%) . 62% . 30% 1% 99% . Streptococcus spp. Enterobacterium spp. Ureaplasma spp. 30% 99%. 104 57 3 . 30% 80% (n=66) (45,5%) . 20% 79% 30 . 1% . : 63% 20 - Gardnerella vaginalis/Prevotella bivia/ Porphyromonas spp. 99%, 23,3% - Eubacterium spp. 20 30%, 20,0% - Lachnobacterium spp./Clostridium spp. 25 99%, 16,7% - Atopobium vaginae 20 80%, spp./Leptotrihia spp./Fusobacterium spp. 21 (70,0%) - Sneathia 40% . Ureaplasma spp, 104 28 20 26,7% 5 – M. hominis . 66 (42,4%) , 20% , 103 Candida spp. . 50% 32 99% . – 20 104 Ureaplasma spp. 103 Candida spp. 80%. 3 , 18 - . (n=115) 6): (n=22), Candida spp. (n=42), (n=8), (n=15) (n=28). 58 , . 6. . 3.2 (n=101) . 95 (94,1%). 59 (62,1%), – 36 (37,9%). 36 18 (50,0%) 104 Ureaplasma spp. , 103 Candida spp. 20 (55,6%) , 2 . 6 (5,9%) 101. – 60%. : Enterobacterium spp. Streptococcus spp. 25%. 59 30% , . (n=24) ( 7): (n=9), (n=9), 103 Candida spp. , (n=6). Ureaplasma spp. , Candida spp. [51; 197]. 2. . 7. 60 2. (n=194) (n=101) 40 42 115 24 14 11 10 16 15 - - 8 ) : ) Candida spp. > 103 <10 : Ureaplasma spp. > 10 <10 , 4 <10 , <10 3.3 : (IL1B, IL6, IL8, IL10, IL12 , IL15, IL18, IL23, IFNG, TNFA, TGFB1, LIF); 61 (TBX21, GATA3, FOXP3, RORC2); (CD45, CD68, CD69, IL2RA(CD25)); (TLR2, TLR4, TLR9); (GNLY). , ( 8). 100,00 10,00 1,00 0,10 0,01 0,00 IL8 IL1B IL18 TGFB1 CD68 GATA3 TNFA CD45 IL12a IL23 TLR2 TLR4 CD69 RORC IL10 IL15 FOXP3 LIF TLR9 GNLY TBX21 IFNG IL6 IL2Ra B2M GUS TBP 0,00 . 8. ( ). 3 : 106 105 (IL8, IL1B, IL18, TGFB1, CD68, GATA3); 105 103 62 (TNFA, CD45, IL12A, IL23, TLR2, TLR4, CD69, RORC, IL10) 103 - (IL15, FOXP3, LIF, TLR9, GNLY, TBX21, IFNG, IL6, IL2RA). , , . 180-600 106 . 3.4 , . 3. 1 . . <0,05. 103 (IL15, FOXP3, LIF, TLR9, GNLY, TBX21, IFNG, IL6, IL2RA) . 2( ). 4 ( ) 5 2 . <0,05. , IL1B 63 4,0, IL8 5,7, TLR2 4,4, TLR4 4,8 . ( , , TNFA , .). IL23 9). 0.01 0.1 1 10 100 ( IL1B* IL8* TNFA TLR2* . 9. TLR4* IL23 IL1B, IL8, TNFA, TLR2, TLR4, IL23 , ( 1 , * <0,05) , CD45 CD69 3,5 3,3 64 10). IL10 3,6 10). 0.01 0.1 1 10 100 ( CD45* CD69* . 10. IL10* CD45, CD69, IL10 , ( 1 , * <0,05). , 65 : IL12A GATA3 8, RORC2 2, TGFB1 8, CD68 3, 2 11). 0.001 0.01 0.1 1 10 ( 4, IL18 CD68* IL12A* IL18* GATA3* . 11. TGFB1* RORC* CD68, IL12A, IL18, GATA3, TGFB1, RORC2 , ( 1 , * <0,05) 66 3. ( 1 ) (n=115) (n=40) Med (0.250.75) spp. Ureaplasma 104 (n=10) Candida spp. 103 (n=14) (n=15) Med (0.250.75) * Med (0.250.75) * Med (0.250.75) * Med (0.250.75) * IL8 1 (0.26-2.26) - 5.7 (2.64-12.93) 3.11*10-11 4.9 (1.30-8.62) 0.02 2,0 (0.40-3.89) 0.38 1.5 (0.56-3.80) 0.27 IL1B 1 (0.47-1.56) - 4.0 (1.76-7.69) 2.03*10-9 2.4 (1.36-4.54) 0.02 0.8 (0.24-2.67) 0.95 1.4 (0.74-3.53) 0.21 CD68 1 (0.56-1.78) - 0.3 (0.17-0.54) 1.13*10-9 0.5 (0.20-0.78) 0.03 0.8 (0.42-2.25) 0.98 0.4 (0.24-1.14) 0.02 IL18 1 (0.72-1.64) - 0.1 (0.04-0.24) 8.50*10-17 0.3 (0.12-0.62) 0.01 0.8 (0.33-2.62) 0.67 0.2 (0.12-0.49) 0.0001 TGFB1 1 (0.68-1.72) - 0.6 (0.39-1.22) 0.003 0.9 (0.44-1.39) 0.24 1.8 (1.25-2.93) 0.02 1.1 (0.65-1.75) 0.91 GATA3 1 (0.56-1.50) - 0.1 (0.04-0.24) 1.90*10-17 0.5 (0.11-0.69) 0.01 1,0 (0.32-1.89) 0.60 0.3 (0.08-0.82) 0.001 CD45 1 (0.34-2.11) - 3.5 (1.76-5.43) 2.43*10-8 2.8 (1.59-3.36) 0.04 0.8 (0.20-1.83) 0.70 1.1 (0.45-2.46) 0.71 3 (n=115) (n=40) Med (0.250.75) Ureaplasma spp. 104 (n=10) Candida spp. 103 (n=14) (n=15) Med (0.250.75) * Med (0.250.75) * Med (0.250.75) * Med (0.250.75) * TNFA 1 (0.59-1.85) - 1.2 (0.53-2.62) 0.35 0.9 (0.46-1.20) 0.39 1.6 (0.42-2.98) 0.49 1.1 (0.39-1.52) 0.64 TLR2 1 (0.54-2.73) - 4.4 (2.24-6.96) 8.39*10-9 5.1 (2.34-8.18) 0.004 1,0 (0.11-3.67) 0.69 2.2 (0.86-3.96) 0.14 TLR4 1 (0.29-1.72) - 4.8 (2.63-7.19) 3.14*10-12 2.5 (1.19-7.16) 0.018 0.6 (0.19-0.88) 0.45 1.8 (0.62-3.75) 0.10 IL23 1 (0.54-2.28) - 0.9 (0.39-2.70) 0.89 1.1 (0.46-1.71) 0.67 2,0 (0.34-6.58) 0.43 0.5 (0.19-1.24) 0.11 CD69 1 (0.62-2.56) - 3.3 (1.67-7.05) 1.59*10-9 3.1 (1.82-7.00) 0.005 1.5 (0.25-2.18) 0.99 1.6 (0.49-2.13) 0.68 IL12A 1 (0.68-1.89) - 0.3 (0.09-0.77) 7.55*10-9 0.4 (0.21-1.72) 0.05 1.0 (0.76-1.39) 0.73 0.4 (0.26-0.56) 0.001 IL10 1 (0.38-2.21) - 3.6 (2.01-6.86) 5.82*10-9 3.1 (1.59-4.77) 0.06 0.9 (0.04-3.97) 0.87 1.6 (1.07-2.25) 0.20 RORC 1. (0.46-1.96) - 0.2 (0.12-0.49) 2.87*10-10 0.7 (0.24-0.77) 0.07 0.7 (0.34-1.49) 0.35 0.8 (0.29-1.25) 0.27 * p - . 68 4. 103 (n=40) (n=115) Ureaplasma spp. 104 (n=10) , Candida spp. 103 (n=14) - (n=194) (n=15) LIF 25 (63%) 70 (61%) 8 (80%) 6 (43%) 9 (60%) 118 (61%) IL15 17 (43%) 69 (60%) 8 (80%) 6 (43%) 9 (60%) 109 (51%) IL6 14 (35%) 96 (84%) 9 (90%) 3 (21%) 11 (73%) 133 (69%) GNLY 24 (60%) 100 (87%) 9 (90%) 7 (50%) 11 (73%) 151 (78%) TLR9 33 (83%) 108 (94%) 10 (100%) 8 (57%) 12 (80%) 171 (88%) FOXP3 35 (88%) 106 (92%) 9 (90%) 10 (71%) 14 (93%) 175 (90%) IFNG 25 (63%) 92 (80%) 7 (70%) 8 (57%) 10 (67%) 142 (73%) IL2RA 11 (28%) 69 (60%) 6 (60%) 3 (21%) 7 (47%) 96 (49%) TBX21 21 (53%) 108 (94%) 7 (70%) 8 (57%) 11 (73%) 155 (80%) 69 5. 2 (n=115) 2 103 Ureaplasma spp. 104 (n=10) 2 , - Candida spp. 103 (n=14) 2 (n=15) 2 LIF 0,0 1,00 0,5 0,50 0,9 0,34 0,0 1,00 IL15 3,0 0,08 3,1 1,00 0,0 1,00 0,7 0,39 IL6 31,5 0,001 7,7 0,007 0,4 0,54 5,0 0,026 GNLY 11,9 0,001 2,0 0,16 0,1 0,74 0,4 0,55 TLR9 3,4 0,06 0,8 0,36 2,4 0,12 0,0 1,00 FOXP3 0,3 0,57 0,0 1,00 1,0 0,33 0,0 0,39 IFNG 4,0 0,045 0,0 0,94 0,0 0,97 0,0 1,00 IL2RA 11,3 0,002 2,5 0,12 0,0 0,93 1,1 0,31 TBX21 33,6 0,4 0,52 0,0 1,00 1,2 0,16 0,001 2 p<0,05 3,84. 70 103 , IL6, GNLY, TBX21, IL2RA, IFNG. , , Th1- 14 . 103 Candida spp. , ( 10). , 2 TGFB1, , . 10 104 Ureaplasma spp , ( 10). , , TLR2 2,4, IL8 3,3 4,9, CD45 GATA3 2,8, CD69 3,1 , 5,1, TLR4 2,5, IL1B - CD68 2,0, IL18 2,2 . IL6. . 15 ( 10). CD68 IL18 4,8, GATA3 4,0 IL12A 2,5, 2,5 . . IL6. , , , ( ) , . : 1]/[ p1 2] = E2Cp2/E1Cp1, p2- , 1 2– . (IL15, FOXP3, LIF, TLR9, GNLY, TBX21, IFNG, IL6, IL2RA) , ( ) . IL1B/CD68, IL10/IL18 12). , . 72 TLR4/GATA3 , . , , , : (n=78) (n=77). (n=40) (n=115) . 2 : 0.001 0.01 0.1 1 10 100 1000 . IL10/IL18* . IL1B/CD68* TLR4/GATA3* 12. , ( 1 , *p<0,05). 73 ( ), : y 0,2 lg IL1B CD 68 0,2 lg IL10 IL18 [IL1B], [CD68], [IL10], [IL18], [TLR4] ( 0,3 lg TLR 4 GATA3 1,0 , [GATA3] – ) . . 95% (19 20) 93% (54 58) ( 13). 4,0 3,0 2,0 1,0 ,0 -1,0 -2,0 -3,0 -4,0 -5,0 -6,0 cut off . 13. . , (n=77). 74 , 95% (73 : 95% (19 96% (55 20) 57) . ROC- ( ROC- (AUC) . 14). 0,98 (p<0,05) ( 15). « ». 25 20 , % 15 10 5 0 -5 -3 -1 1 3 5 cut off . 14. . 75 77) ROC- . 15. ROC( ). ( cut off) , , -0,61. 96% 95% . cut off . : , 40% 86% 47% 6). 76 6. , , , 4 Candida spp. > 10 (n=14) Ureaplasma spp. > 104 (n=10) (n=15) 86% (12 14) 14% (2 14) 40% (4 10) 60% (6 10) 47% (7 15) 53% (8 15) cut off 16. . 16. . 77 3.5 , , , . 7. 1 . . <0,05. 103 (IL15, FOXP3, LIF, TLR9, GNLY, TBX21, IFNG, IL6, IL2RA) . 2( ). 8 ( 9 ) 2 . <0,05. , , LIF IL15 , , 2 . , 78 IL1B TLR2 8,0, TLR4 9,4, IL8 6,0, 7,3 . , TNFA 5,3 IL15 2,3, LIF 2,5 . ( , , , NK- , .). IL23 17). 0.01 0.1 1 10 100 ( IL1B* IL8* TNFA* . 17. TLR2* TLR4* IL23 IL1B, IL8, TNFA, TLR2, TLR4, IL23 , ( 1 ). 79 7. ( 1 ) (n=42) Med (0.250.75) * IL8 1 (0.41-0.98) IL1B , Ureaplasma spp. 104 (n=16) (n=24) Candida spp 103 (n=11) Med (0.25* 0.75) (n=8) Med (0.250.75) * 0.03 0.7 (0.45-1.43) 0.60 0.7 (0.50-1.47) 0.21 1.2 (0.74-3.29) 0.50 0.07 0.6 (0.38-0.73) 0.004 1.2 (1.08-1.45) 0.10 0.7 (0.37-1.54) 0.38 0.6 (0.42-0.90) 0.01 1.2 (1.19-1.49) 0.21 0.0004 1.2 (0.60-1.94) 0.91 0.7 (0.44-0.78) 0.02 2.4 (1.11-2.81) 0.29 0.3 (0.16-0.39) 4.11*10-8 0.9 (0.48-1.31) 0.31 0.5 (0.37-0.76) 0.004 2.3 (1.77-4.34) 0.008 - 5.7 (4.18-9.46) 4.96*10-8 0.8 (0.39-1.41) 0.27 0.9 (0.49-1.54) 0.39 0.9 (0.60-3.54) 0.76 - 2.3 (1.49-4.02) 0.0009 1.3 (0.65-3.09) 0.49 0.8 (0.58-1.10) 0.28 0.8 (0.48-1.73) 0.40 Med (0.25-0.75) * Med (0.25-0.75) * - 6,0 (2.71-11.84) 3.18*10-7 1.3 (0.29-2.19) 0.70 0.5 (0.41-0.57) 1 (0.58-2.36) - 9.4 (6.61-11.90) 2.01*10-9 1.4 (0.41-2.02) 0.84 CD68 1 (0.67-1.59) - 0.4 (0.22-0.56) 5.75*10-7 0.7 (0.48-1.09) IL18 1 (0.63-1.54) - 0.2 (0.14-0.45) 4.98*10-8 TGFB1 1 (0.59-2.51) - 0.4 (0.23-0.87) GATA3 1 (0.65-1.40) - CD45 1 (0.46-2.08) TNFA 1 (0.63-1.86) 7 (n=42) Med (0.250.75) * TLR2 1 (0.45-2.15) TLR4 , Ureaplasma spp. 104 (n=16) (n=24) Candida spp 103 (n=11) Med (0.25* 0.75) Med (0.25-0.75) * Med (0.250.75) * - 8,0 (4.97-12.44) 1.07*10-7 1.1 (0.17-3.15) 0.50 0.9 (0.27-1.04) 1 (0.32-2.34) - 7.3 (4.90-12.74) 9.09*10-8 1.1 (0.22-2.34) 0.76 IL23 1 (0.48-2.53) - 1.5 (0.51-6.11) 0.18 0.6 (0.36-1.60) CD69 1 (0.39-3.43) - 5.4 (2.15-14.82) 0.00098 IL12A 1 (0.72-1.48) - 0.5 (0.26-0.91) IL10 1 (0.55-2.24) - RORC (n=8) Med (0.250.75) * 0.09 0.8 (0.37-1.39) 0.35 0.6 (0.43-1.34) 0.45 1.3 (0.64-2.08) 0.67 0.43 0.9 (0.70-4.34) 0.37 0.4 (0.26-0.93) 0.09 1.5 (0.39-1.26) 0.11 1.0 (0.73-2.11) 0.80 2.8 (1.85-5.28) 0.09 0.0003 0.9 (0.63-1.57) 0.67 0.6 (0.50-1.15) 0.08 1.1 (0.96-1.82) 0.55 4.2 (3.33-7.98) 5.98*10-8 1.9 (0.89-4.70) 0.06 2.1 (1.54-3.30) 0.02 1.3 (0.60-1.86) 0.82 1 (0.64-2.90) 0.2 (0.09-0.71) 0.00003 0.7 (0.32-2.00) 0.23 0.3 (0.18-0.96) 0.02 3.3 (2.08-6.13) 0.07 LIF 1 (0.40-2.48) 5.3 (2.94-35.54) 0.0001 0.8 (0.40-2.55) 0.49 0.3 (0.10-0.43) 0.001 1.1 (0.75-2.61) 0.98 IL15 1 (0.63-2.36) 2.5 (1.57-3.50) 0.01 3.1 (1.43-5.47) 0.02 1.9 (1.47-3.22) 0.09 1.8 (1.19-2.76) 0.17 * p . 81 8. 103 (n=42) (n=24) LIF 42 (98%) 24 (100%) Ureaplasma spp. 104 (n=16) 16 (100%) IL15 42 (100%) 24 (100%) IL6 27 (64%) GNLY , 3 Candida spp 10 (n=11) (n=101) 11 (100%) (n=8) 8 (100%) 101 (100%) 16 (100%) 11 (100%) 8 (100%) 100 (100%) 23 (96%) 11 (69%) 10 (91%) 6 (75%) 76 (75%) 31 (74%) 24 (100%) 10 (63%) 6 (55%) 4 (50%) 75 (74%) TLR9 36 (86%) 24 (100%) 10 (63%) 8 (73%) 4 (50%) 82 (81%) FOXP3 36 (86%) 19 (79%) 14 (88%) 8 (73%) 4 (50%) 81 (80%) IFNG 24 (57%) 17 (71%) 11 (69%) 10 (91%) 0 (0%) 62 (61%) IL2RA 19 (45%) 21 (88%) 6 (38%) 6 (55%) 5 (63%) 57 (56%) TBX21 24 (57%) 18 (75%) 10 (63%) 8 (73%) 4 (50%) 64 (63%) 9. 2 103 (n=24) 104 Ureaplasma spp. (n=16) 2 2 , 3 Candida spp 10 (n=11) 2 (n=8) 2 IL6 6,7 0,01 0,0 0,99 4,0 0,045 0,0 0,86 GNLY 5,8 0,02 0,2 0,60 0,7 0,39 0,8 0,36 TLR9 2,2 0,13 1,2 0,27 0,3 0,57 3,3 0,07 FOXP3 0,1 0,73 0,0 1,00 0,3 0,57 3,3 0,07 IFNG 4,0 0,045 0,2 0,61 3,8 0,08 6,6 0,01 IL2RA 9,7 0,003 0,1 0,81 0,1 0,83 0,2 0,61 TBX21 1,4 0,24 0,0 0,94 0,3 0,55 0,0 1,00 2 p<0.05 3,8 83 , CD45 5,7 CD69 5,4 18). 0.01 0.1 1 10 100 ( CD45* CD69* IL10* . 18. LIF* IL15* CD45, CD69, IL10, LIF, IL15 , ( ). IL10 ( 4,2 18). CD68 2,5, IL12A 1 2,0, IL18 5,0, GATA3 3,3, TGFB1 2,5 RORC 19). 0.001 0.01 0.1 1 10 ( 5,0 CD68* IL12A* IL18* GATA3* . 19. TGFB1* RORC* CD68, IL12A, IL18, GATA3, TGFB1, RORC , ( 1 ). 103 , IL6, GNLY, IL2RA IFNG. . 11 103 Candida spp. 85 , ( 10). IL8 2,0, IL18 1,6, TGFB1 – IL10 1,4, GATA3 2,0, RORC 3,0 LIF 4,0 2,1 . IL6. 16 104 Ureaplasma spp , ( 10). , , IL15, 2 . (n=8) , GATA3, 2 , . , : IL1B/CD68, IL10/IL18 TLR4/GATA3. , , ( ) . 86 10. 10. ( 1 ) (n=40) (n=42) (0,25-0,75) * (0,25-0,75) * IL1B 1 (0,45-1,56) - 0,6 (0,30-1,40) 0,09 IL8 1 (0,28-2,41) - 0,9 (0,37-1,81) 0,52 IL10 1 (0,39-2,23) - 2,4 (1,32-5,45) 0,004 IL12A 1 (0,69-1,89) - 1,8 (1,32-2,72) 0,021 IL18 1 (0,69-1,73) - 0,8 (0,52-1,28) 0,002 TNFA 1 (0,59-1,90) - 0,6 (0,34-1,01) 0,001 TGFB1 1 (0,69-1,81) - 12,7 (7,55-31,82) 1,2*10-13 CD45 1 (0,31-2,11) - 0,5 (0,23-1,04) 0,01 TLR2 1 (0,54-2,73) - 0,6 (0,25-1,20) 0,07 TLR4 1 (0,29-1,72) - 0,6 (0,19-1,40) 0,46 IL23 1 (0,54-2,28) - 0,9 (0,45-2,38) 0,84 GATA 3 1 (0,56-1,50) - 0,8 (0,52-1,12) 0,34 CD68 1 (0,56-1,78) - 1,6 (1,08-2,56) 0,005 CD69 1 (0,62-2,56) - 1,3 (0,49-4,39) 0,84 * p . 87 IL10 2,4, IL12A 18, TGFB1 12,7 IL18 1,2, TNFA 1,8 CD68 CD45 1,6 , 2,1 ( 20). , , 0 .1 1 10 ). IL1B IL8 IL10* IL12A* IL18* TNFA* TGFB1* CD45* TLR2 TLR4 IL23 GATA3 CD68* . 20. , . 1 (*p<0,05) . : y 0,5 lg IL1B CD 68 0,3 lg IL10 IL18 88 0,04 lg TLR 4 GATA3 1,3 , CD69 [IL1B], [CD68], [IL10], [IL18], [TLR4] ( [GATA3] – ) . , , 0.001 0.01 0.1 1 10 100 1000 21. IL10/IL18* . IL1B/CD68* TLR4/GATA3* 21. , ( (*p<0,05)). 95% (40 96% (23 24) . ( 22). 89 42) 1 35 30 25 ,% 20 15 10 5 0 -3 -2 -1 0 1 2 3 4 5 6 cut off . 22. . ROC(AUC) . 0,993 (p<0,05) ( ROC- 23). ». ( cut off) , . 0,65. 96% 95% . cut off . 90 ROC- . 23. ROC( ). : 82% Ureaplasma spp. , 75% 104 , ( 11). 91 11. , , , 4 Candida spp. > 10 (n=11) Ureaplasma spp. >104 (n=16) (n=8) 82% (9 11) 18% (2 11) 75% (12 16) 25% (4 16) 100% (8 8) 0% (0 8) cut off 24. . 24. 92 3.6 , (p=1,3*10-5, =10,4 3,28-32,94). , ( 12). 12. (n=42) 7 % 16,7 7 (n=24) % 29,2 1 2,4 7 29,2* , 3 7,1 6 25,0* , 3 7,1 4 16,7 9 21,4 2 13 8,3* 54,2* . . : *– ( <0,05) : (7,8%) 7 (29,2%) (p=0,012, 16.10). 93 6 =4.87, 1.48- 6 (25,0%) , 6 (7,8%) ( =0,033, =3.94, 1.16-13.44). , . 7 , 9 (77,7%) 104 Candida spp. . , Candida spp. . IL1B, IL8, IL10, D45, CD69, TLR2, TLR4, TNF , GATA3, CD68, IL12A, IL18, TGFB1, RORC ( , ) ( , ) . , , . 94 4. . , , , , [47]. , [4]. . , : ), . , . , , , [109; 110]. , , L. crispatus, L. iners, L. jensenii L.gasseri [150]. , . , . , , , , [16; 60]. 95 . [50; 53; 58]. , [16; 60]. , [102; 146; 168], , : , , - . , , , . , 81% , Streptococcus spp., Enterobacterium spp., Gardnerella vaginalis/Prevotella bivia/Porphyromonas spp., Eubacterium spp., Lachnobacterium spp./Clostridium spp., Atopobium vaginae, Sneathia spp./Leptotrihia spp./Fusobacterium spp.) . 19% . 63% , . 96 37% - (IL1B, IL6, IL8, IL10, IL12A, IL15, IL18, IL23, TNF , IFNG, TGFB1, LIF, TBX21, GATA3, FOXP3, RORC, TLR2, TLR4, TLR9, CD45, CD68, CD69, IL2R , GNLY) ( - ). , , , , , . , TLR2, TLR4, IL1B, IL8, IL6, IL10, CD45, CD69, IL2RA, IFNG GNLY, CD68, IL12A, IL18, GATA3, RORC, TGFB1 . LIF, IL15 TNFA , – TBX21 . , . . , PAMP, : , , , , [131]. PRR TLRs, APC, [174]. 97 , TLRs [111; 124]. PAMP TLR1, -2, -4, -6, [144; 191]. [144; 163; 171; 189] , , , , , , TLR2, -4, -6, TLR2 TLR4. PRR , , ), . , TLRs , (NF-kB), (NF-kB) , , , . , IL1A, IL1B, IL8, IL6, IL18, IL12, TNFA [26; 85; 105; 107; 157], IL6 [106; , 120]. ( , , NK- .) . IL8. , , , , . 98 (IL1B, IL6, IL8, TNFA) , , . . , – NK- - . [103; 136], , . GNLY. ( TLRs, ) , . , , APC MHC - [102; 172]. [27; 165; 175] CD68, . CD68 . , , CD68. 99 . TBX21 INFG - . INFG, , . – , CD8+-T- – Th1- . TBX21 , Th0Th1- , - [132; 180]. TBX21, IFNG , IL18, , IL12 Th0, . IL12A IL12, Th1, IL18. , , [87; 101; 118]. , IL2Ra, CD69, CD45 . , . . 2-3 CD69 – 100 , CD25, - a- - IL-2 [74; 158]. - CD45 , , , [127; 176]. IL15 . IL-15 , . , : CD8+ , IFNG - , TNFA [77; 82; 89]. IL10, [79; 141; 194]. , , IL10, , , . , IL10 , , CD4+ , IL10 - CD8+ NKCD4+ - – , (IL2, IFNG, IL4, IL5, TNFA), – : MHC II (IL1A . IL10 , B, IL6, IL12, IL18, TNFA) 101 ; , . , IL10 [98]. IL10, , Th17- . RORC , [183]. 40% Candida spp. , , . , Candida spp. , IL10 TGFB1[69]. IL10 TGFB1 . , , , [86; 148]. , TGFB1 . , , , [133], , , . GATA3, Th2- , , ( 102 ) [95; 135]. GATA3 . , , IL10, IL12A, TGFB1 TNFA, CD45 – CD68, IL18, , . LIF, IL15, GNLY IFNG . NK- , [145; 156]. , , . , (GNLY, IL2RA, IL15, IFNG, TBX21, IL6, LIF, FOXP3) , , , , . , (p=1,3*10-5, =10,4 3,28-32,94). , IL1B, IL8, IL10, D45, CD69, TLR2, TLR4, TNF , GATA3, CD68, IL12A, IL18, TGFB1, RORC 5-3 103 , . , . 7 , 9 (77,7%) . , , 40% , [170], . IL1B, CD68, IL10, IL18, TLR4 96% GATA3 95% , . . , , , . , , , , , , [32]. 104 , . , , , . , « », - : , 104 Ureaplasma spp. . , . , : 14% , 60% 53% . , IL1B, CD68, IL10, IL18, TLR4 GATA3 . , , . 105 , , . . 106 1. , . 2. (24 14 (IL1B, IL8, IL10, ) D45, CD69, TLR2, TLR4, TNF , GATA3, CD68, IL12A, IL18, TGFB1, RORC) . 3. ( IL1B, IL8, IL10, TLR2, TLR4, TNF RORC , D45, CD69, GATA3, CD68, IL12A, IL18, TGFB1, ), . 4. IL10, IL12A, TGFB1, CD68 – IL18, TNFA, CD45 . 5. IL1B, IL8, IL10, D45, CD69, TLR2, TLR4, TNF , GATA3, CD68, IL12A, IL18, TGFB1, RORC ( , ) ( , ) . 6. IL1B, IL18, IL10, CD68, TLR4 GATA3 96% , 95% . 107 1. . ., . ., . : . / ., . .: « . », 2009. - 1200 c. 2. . . ./ 3. . .: " ., ", 2009. - 73 c. . . // 2001 - . 3 4. . ., . 2. . 24-27 . . //Concilium medicum. 2005. - . 51-64. 5. . . – //Consilium Medicum 2011 - . 13 6. . 4. . 7-11 ., . . : . / .: " ", 2008. - 256 . c. 7. . . . // 8. . 2010. - . 12 . ., . 3. . 4-6. ., . . - . //Consilium medicum. 2009. 9. 6. . 47-51. . ., . ., . . . // 10. . 2005. . 3. . 65-69. ., . 108 ., . . . . 2009. - . 27 11. . // 4. . 114–116. ., . ., . ., . . . ., : ? // . 2011. - 12. . ., . 1. . 57-65. ., . . - . 2009 - 1. . 34-36 13. . . . // . 2007. - . 4 1. . 6- 8. 14. . ., . . . 2009. - . . // 1. . 19-22. 15. . ., . // 16. ., . . . . 2007. - ., . 2. . 11-12. . . // 17. . ., . 2008. - 1. . 7-9. . . // , . 2001. - 4. . 89-93. 18. . . ., . . ., . 2012 . 3. . 88-93 . // . . . 2003. - . 11 17. . 985-989. 20. ., . // 19. ., . ., . ", 2008. - 552 . c. 109 . . / .: 21. . . . ., ./ : « », 2001. - 364 c. 22. . ., . ., . . . // . 2010. 23. . ., 5. . 127-135. . . . // . 2008. - 5. . 8-14. 24. . ., . ., . . - . . 2009. - 25. . ., . // 1. . 34-37. ., . . , . // 2010 - . 13 . 4. . 95-97. 26. . ., . . . 2012 - 27. . ., . // , 4. . 114-118 ., . . . . . // 2003 - 3. . 3-17. 28. . ., . ., . . . / :« 29. . », 2006. - 1056 c. . ., ., . A., . . ., . . . // 110 ., . - . 12. . . 2010. 22 (93). . 25-31. 30. E. B. . . 2008. - 31. . . // 1. . 13-16. , , // . 2009. - 32. . ., . . ., . ., . 1. . 29-31. ., . . ., , , ( )/ 33. . ., . : 2009. - 43 . c. . . . 2009. - 34. . ., . . // 35. . 1. . 15-16. . : . 2009. - 3. . 50-53. . 2008 - . 10 4. . 9-13. . . // 36. // . ., . . / .: « », 2011. - 751 . c. 37. . ., . ., . . ? // 2012 - : 38. . ., . . . 2004 - . 6 39. . ., . . . ., . . 2009. - . 11 . 1. . 53-67. 111 4. . 36-39. : -5 2009. - . 13 // 3. . 18-24 . // 40. 4. . 12-15 . // . 41. . ., . . . / :« 42. », 2007. - 53 c. . 43. . . – . // 2005. - ., . ., 114. . 3-5. . ., . ., . . // 2010 - . 9 44. . , 5. . 5-9 ., . . , . // . 2005. - 45. . ., . 4. . 18-20. . , . // . 2007. - 46. . ., . 4. . 36-39. . . // . 2006. - . 5 47. . ., . ./ 48. . ., . ., 6. . 7-12. ., . .: « . , . », 2009. - 256 c. ., . ., . ., . . ( ). / : ., 2003. - 53 c. 49. . 50. // ., . ., . . // 2011. - . 13 . ., . . : . 5. . 30-36. - . . 2005 - 112 , 2. . 47-50 51. . ., , . . , . . / .: « », 2010. - 80 c. 52. . ., . . : . // 2011. - . 14 4. . 47-50. 53. . ., . ., . ., . . ., . ., 2007 - . 9 1. . . . , . // 54. . . 2010 - . 12 ., . ., . ., 2. . 6-9 . ., . . ., . // 13-17 55. . ., . . // ., . 2004. - . 6 56. . ., 2009. - . . . 2006 - ., . ., 3. // 57. . 2. . 5-8 . . // 1. . 9-12. 58. . . ? // 2001 - 59. . ., . 19. . 843-846. . : . . 2009. - 60. . ., . ., . 2005. - . 4 . // 6. . 102-106. . . 61. . . // , 1. . 66–71. . . // 2005. 113 2. . 7-9. 62. . ., . ., . ., . . , . // . 2010. - . 12 5. . 10-14. 63. . ., . ( // ., . . ) . 2004. - 64. . . 2. . 73-76. ., . ., . . : ? // . . » 2012 - . 6 1. . 6-13 65. . ./ ., . .: " ., . ., ", 2003. - 140 c. 66. . . . ? //Consilium Medicum 2011 - . 13 67. . ., . . 2007. - . 9 6. . 37-41 . // 68. . . : 2. . 54-58. . ., . . . // . 2004. - 13. . 752-754. 69. . . // 2009 - . 11 1. . 3-10 70. . . : . // . 2008. - . 252 71. . ., // . . 2011 - 72. . ., . ., 15. . 12-16. 6. . 36-40 . . ., ., . ., . 114 ., . ., . ., . . . // 73. 2009. . ., . – « . 2010. - . 13 74. . » ., . « » 3. . 38-44. . ? // 4. . 164-168. . : ./ : , 2010. - 752 c. 75. ACOG Practice Bulletin. Clinical management guidelines for obstetriciangynecologists, Number 72, May 2006: Vaginitis // Obstetrics and gynecology. 2006. - Vol. 107. - 5. - P. 1195-1206. 76. Aagaard K., Riehle K., Ma J., Segata N., Mistretta T. A., Coarfa C., Raza S., Rosenbaum S., Van den Veyver I., Milosavljevic A., Gevers D., Huttenhower C., Petrosino J., Versalovic J. A metagenomic approach to characterization of the vaginal microbiome signature in pregnancy // PloS one. - 2012. - Vol. 7. - 6. - P. e36466. 77. Ahmad R., El Bassam S., Cordeiro P., Menezes J. Requirement of TLR2mediated signaling for the induction of IL-15 gene expression in human monocytic cells by HSV-1 // Blood. - 2008. - Vol. 112. - 6. - P. 2360-2368. 78. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity // Cell. - 2006. - Vol. 124. - 4. - P. 783-801. 79. Anderson B. L., Cu-Uvin S., Raker C. A., Fitzsimmons C., Hillier S. L. Subtle perturbations of genital microflora alter mucosal immunity among lowrisk pregnant women // Acta obstetricia et gynecologica Scandinavica. - 2011. Vol. 90. - 5. - P. 510-515. 80. Anderson M. R., Klink K., Cohrssen A. Evaluation of vaginal complaints // JAMA : the journal of the American Medical Association. - 2004. - Vol. 291. 11. - P. 1368-1379. 81. Anton G., Rid J., Mylonas I., Friese K., Weissenbacher E. R. Evidence of a TH1-shift of local vaginal inflammatory response during bacterial vaginosis // Infection. - 2008. - Vol. 36. - 2. - P. 147-152. 115 82. Barlic J., McDermott D. H., Merrell M. N., Gonzales J., Via L. E., Murphy P. M. Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms // The Journal of biological chemistry. - 2004. - Vol. 279. - 47. - P. 48520- 48534. 83. Barton G. M., Kagan J. C. A cell biological view of Toll-like receptor function: regulation through Immunology. - 2009. - Vol. 9. - compartmentalization // Nature reviews. 8. - P. 535-542. 84. Beagley K. W., Gockel C. M. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone // FEMS immunology and medical microbiology. - 2003. - Vol. 38. - 1. - P. 13-22. 85. Beigi R. H., Yudin M. H., Cosentino L., Meyn L. A., Hillier S. L. Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis // The Journal of infectious diseases. - 2007. - Vol. 196. - 9. - P. 1355-1360. 86. Benoit M., Desnues B., Mege J. L. Macrophage polarization in bacterial infections // Journal of immunology. - 2008. - Vol. 181. - 6. - P. 3733-3739. 87. Biet F., Locht C., Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens // Journal of molecular medicine. - 2002. - Vol. 80. - 3. - P. 147-162. 88. Bohbot J. M., Sednaoui P., Verriere F., Achhammer I. [The etiologic diversity of vaginitis] // Gynecologie, obstetrique & fertilite. - 2012. - Vol. 40. - 10. - P. 578-581. 89. Brincks E. L., Woodland D. L. Novel roles for IL-15 in T cell survival // F1000 biology reports. - 2010. - Vol. 2. - P. 67. 90. Campos A. C., Murta E. F., Michelin M. A., Reis C. Evaluation of Cytokines in Endocervical Secretion and Vaginal pH from Women with Bacterial Vaginosis or Human Papillomavirus // ISRN obstetrics and gynecology. - 2012. - Vol. 2012. - P. 342075. 91. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., Demengeot J. Regulatory T cells selectively express toll-like receptors and are 116 activated by lipopolysaccharide // The Journal of experimental medicine. - 2003. Vol. 197. - 4. - P. 403-411. 92. Casari E., Ferrario A., Morenghi E., Montanelli A. Gardnerella, Trichomonas vaginalis, Candida, Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum in the genital discharge of symptomatic fertile and asymptomatic infertile women // The new microbiologica. - 2010. - Vol. 33. 1. - P. 69-76. 93. Cassone A., De Bernardis F., Santoni G. Anticandidal immunity and vaginitis: novel opportunities for immune intervention // Infection and immunity. - 2007. - Vol. 75. - 10. - P. 4675-4686. 94. Chaturvedi A., Pierce S. K. How location governs toll-like receptor signaling // Traffic. - 2009. - Vol. 10. - 6. - P. 621-628. 95. Chou J., Provot S., Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! // Journal of cellular physiology. - 2010. Vol. 222. - 1. - P. 42-49. 96. Colonna M., Trinchieri G., Liu Y. J. Plasmacytoid dendritic cells in immunity // Nature immunology. - 2004. - Vol. 5. - 12. - P. 1219-1226. 97. Coolen M. J., Post E., Davis C. C., Forney L. J. Characterization of microbial communities found in the human vagina by analysis of terminal restriction fragment length polymorphisms of 16S rRNA genes // Applied and environmental microbiology. - 2005. - Vol. 71. - 12. - P. 8729-8737. 98. Couper K. N., Blount D. G., Riley E. M. IL-10: the master regulator of immunity to infection // Journal of immunology. - 2008. - Vol. 180. - 9. - P. 5771-5777. 99. Creagh E. M., O'Neill L. A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity // Trends in immunology. - 2006. Vol. 27. - 8. - P. 352-357. 100. Cummins J. E., Jr., Doncel G. F. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety // Sexually transmitted diseases. - 2009. Vol. 36. - 3 Suppl. - P. S84-91. 117 101. Cunningham A. L., Harman A., Kim M., Nasr N., Lai J. Immunobiology of Dendritic Cells and the Influence of HIV Infection // Advances in experimental medicine and biology. - 2013. - Vol. 762. - P. 1-44. 102. de Jong M. A., Geijtenbeek T. B. Human immunodeficiency virus-1 acquisition in genital mucosa: Langerhans cells as key-players // Journal of internal medicine. - 2009. - Vol. 265. - 1. - P. 18-28. 103. Doaa M. Mahgoub, Nermine H. EL-Eishi, Rashed L. A. A Quantitative Study of the Antimicrobial Peptide Granulysin and its Possible Role in Atopic Dermatitis // J Egypt Women Dermatol Soc. - 2010. - Vol. 7. - 2. - P. 117-122. 104. Donati L., Di Vico A., Nucci M., Quagliozzi L., Spagnuolo T., Labianca A., Bracaglia M., Ianniello F., Caruso A., Paradisi G. Vaginal microbial flora and outcome of pregnancy // Archives of gynecology and obstetrics. - 2010. - Vol. 281. - 4. - P. 589-600. 105. Donders G. G., Vereecken A., Bosmans E., Dekeersmaecker A., Salembier G., Spitz B. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis // BJOG : an international journal of obstetrics and gynaecology. - 2002. - Vol. 109. - 1. - P. 34-43. 106. Donders G. G., Vereecken A., Bosmans E., Spitz B. Vaginal cytokines in normal pregnancy // American journal of obstetrics and gynecology. - 2003. Vol. 189. - 5. - P. 1433-1438. 107. Dongari-Bagtzoglou A., Fidel P. L., Jr. The host cytokine responses and protective immunity in oropharyngeal candidiasis // Journal of dental research. 2005. - Vol. 84. - 11. - P. 966-977. 108. Fan A. P., Xue F. X. [Clinical characteristics of aerobic vaginitis and its mixed infections.] // Zhonghua fu chan ke za zhi. - 2010. - Vol. 45. - 12. - P. 904-908. 109. Farage M., Maibach H. Lifetime changes in the vulva and vagina // Archives of gynecology and obstetrics. - 2006. - Vol. 273. - 4. - P. 195-202. 110. Farage M. A., Maibach H. I. Morphology and physiological changes of genital skin and mucosa // Current problems in dermatology. - 2011. - Vol. 40. P. 9-19. 118 111. Fazeli A., Bruce C., Anumba D. O. Characterization of Toll-like receptors in the female reproductive tract in humans // Human reproduction. - 2005. - Vol. 20. - 5. - P. 1372-1378. 112. Fichorova R. N., Richardson-Harman N., Alfano M., Belec L., Carbonneil C., Chen S., Cosentino L., Curtis K., Dezzutti C. S., Donoval B., Doncel G. F., Donaghay M., Grivel J. C., Guzman E., Hayes M., Herold B., Hillier S., Lackman-Smith C., Landay A., Margolis L., Mayer K. H., Pasicznyk J. M., Pallansch-Cokonis M., Poli G., Reichelderfer P., Roberts P., Rodriguez I., Saidi H., Sassi R. R., Shattock R., Cummins J. E., Jr. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study // Analytical chemistry. - 2008. - Vol. 80. 12. - P. 4741-4751. 113. Fidel P. L., Jr. History and update on host defense against vaginal candidiasis // American journal of reproductive immunology. - 2007. - Vol. 57. 1. - P. 2-12. 114. Forsum U., Hallen A., Larsson P. G. Bacterial vaginosis--a laboratory and clinical diagnostics enigma // APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. - 2005. - Vol. 113. - 3. - P. 153-161. 115. Fredricks D. N., Fiedler T. L., Marrazzo J. M. Molecular identification of bacteria associated with bacterial vaginosis // The New England journal of medicine. - 2005. - Vol. 353. - 18. - P. 1899-1911. 116. Genc M. R., Onderdonk A. Endogenous bacterial flora in pregnant women and the influence of maternal genetic variation // BJOG : an international journal of obstetrics and gynaecology. - 2011. - Vol. 118. - 2. - P. 154-163. 117. Gomez L. M., Sammel M. D., Appleby D. H., Elovitz M. A., Baldwin D. A., Jeffcoat M. K., Macones G. A., Parry S. Evidence of a gene-environment interaction that predisposes to spontaneous preterm birth: a role for asymptomatic bacterial vaginosis and DNA variants in genes that control the inflammatory response // American journal of obstetrics and gynecology. - 2010. - Vol. 202. 4. - P. 386 e381-386. 119 118. Hamza T., Barnett J. B., Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications // International journal of molecular sciences. 2010. - Vol. 11. - 3. - P. 789-806. 119. Heath W. R., Belz G. T., Behrens G. M., Smith C. M., Forehan S. P., Parish I. A., Davey G. M., Wilson N. S., Carbone F. R., Villadangos J. A. Crosspresentation, dendritic cell subsets, and the generation of immunity to cellular antigens // Immunological reviews. - 2004. - Vol. 199. - P. 9-26. 120. Hedges S. R., Barrientes F., Desmond R. A., Schwebke J. R. Local and systemic cytokine levels in relation to changes in vaginal flora // The Journal of infectious diseases. - 2006. - Vol. 193. - 4. - P. 556-562. 121. Hemalatha R., Ramalaxmi B. A., KrishnaSwetha G., Kumar P. U., Rao D. M., Balakrishna N., Annapurna V. Cervicovaginal inflammatory cytokines and sphingomyelinase in women with and without bacterial vaginosis // The American journal of the medical sciences. - 2012. - Vol. 344. - 1. - P. 35-39. 122. Hickey D. K., Patel M. V., Fahey J. V., Wira C. R. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections // Journal of reproductive immunology. - 2011. - Vol. 88. - 2. - P. 185-194. 123. Hill J. E., Goh S. H., Money D. M., Doyle M., Li A., Crosby W. L., Links M., Leung A., Chan D., Hemmingsen S. M. Characterization of vaginal microflora of healthy, nonpregnant women by chaperonin-60 sequence-based methods // American journal of obstetrics and gynecology. - 2005. - Vol. 193. 3 Pt 1. - P. 682-692. 124. Horne A. W., Stock S. J., King A. E. Innate immunity and disorders of the female reproductive tract // Reproduction. - 2008. - Vol. 135. - 6. - P. 739-749. 125. Hornef M. W., Bogdan C. The role of epithelial Toll-like receptor expression in host defense and microbial tolerance // Journal of endotoxin research. - 2005. - Vol. 11. - 2. - P. 124-128. 126. Hyman R. W., Fukushima M., Diamond L., Kumm J., Giudice L. C., Davis R. W. Microbes on the human vaginal epithelium // Proceedings of the National 120 Academy of Sciences of the United States of America. - 2005. - Vol. 102. - 22. - P. 7952-7957. 127. Im M., Chae H., Kim T., Park H. H., Lim J., Oh E. J., Kim Y., Park Y. J., Han K. Comparative quantitative analysis of cluster of differentiation 45 antigen expression on lymphocyte subsets // The Korean journal of laboratory medicine. 2011. - Vol. 31. - 3. - P. 148-153. 128. Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines // Nature reviews. Immunology. - 2010. - Vol. 10. - 10. - P. 699-711. 129. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses // Nature immunology. - 2004. - Vol. 5. - 10. - P. 987-995. 130. Izcue A., Powrie F. Special regulatory T-cell review: Regulatory T cells and the intestinal tract--patrolling the frontier // Immunology. - 2008. - Vol. 123. 1. - P. 6-10. 131. Janeway C. A., Jr., Medzhitov R. Innate immune recognition // Annual review of immunology. - 2002. - Vol. 20. - P. 197-216. 132. Jenner R. G., Townsend M. J., Jackson I., Sun K., Bouwman R. D., Young R. A., Glimcher L. H., Lord G. M. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes // Proceedings of the National Academy of Sciences of the United States of America. - 2009. - Vol. 106. - 42. - P. 17876-17881. 133. Juuti-Uusitalo K. M., Kaukinen K., Maki M., Tuimala J., Kainulainen H. Gene expression in TGFbeta-induced epithelial cell differentiation in a threedimensional intestinal epithelial cell differentiation model // BMC genomics. 2006. - Vol. 7. - P. 279. 134. Kelsall B. L., Rescigno M. Mucosal dendritic cells in immunity and inflammation // Nature immunology. - 2004. - Vol. 5. - 11. - P. 1091-1095. 135. Kouros-Mehr H., Slorach E. M., Sternlicht M. D., Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland // Cell. - 2006. - Vol. 127. - 5. - P. 1041-1055. 136. Krensky A. M., Clayberger C. Biology and clinical relevance of granulysin // Tissue antigens. - 2009. - Vol. 73. - 3. - P. 193-198. 121 137. Kumar H., Kawai T., Akira S. Toll-like receptors and innate immunity // Biochemical and biophysical research communications. - 2009. - Vol. 388. - 4. - P. 621-625. 138. Lamont R. F., Taylor-Robinson D. The role of bacterial vaginosis, aerobic vaginitis, abnormal vaginal flora and the risk of preterm birth // BJOG : an international journal of obstetrics and gynaecology. - 2010. - Vol. 117. - 1. - P. 119-120; author reply 120-111. 139. Larsen B., Hwang J. Mycoplasma, Ureaplasma, and adverse pregnancy outcomes: a fresh look // Infectious diseases in obstetrics and gynecology. - 2010. - Vol. 2010. 140. LeBlanc D. M., Barousse M. M., Fidel P. L., Jr. Role for dendritic cells in immunoregulation during experimental vaginal candidiasis // Infection and immunity. - 2006. - Vol. 74. - 6. - P. 3213-3221. 141. Lilic D., Gravenor I., Robson N., Lammas D. A., Drysdale P., Calvert J. E., Cant A. J., Abinun M. Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasis // Infection and immunity. - 2003. - Vol. 71. - 10. - P. 5690-5699. 142. Linhares I. M., Giraldo P. C., Baracat E. C. [New findings about vaginal bacterial flora] // Revista da Associacao Medica Brasileira. - 2010. - Vol. 56. 3. - P. 370-374. 143. Makela S. M., Strengell M., Pietila T. E., Osterlund P., Julkunen I. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells // Journal of leukocyte biology. - 2009. - Vol. 85. - 4. - P. 664-672. 144. Mares D., Simoes J. A., Novak R. M., Spear G. T. TLR2-mediated cell stimulation in bacterial vaginosis // Journal of reproductive immunology. - 2008. - Vol. 77. - 1. - P. 91-99. 145. Mariee N., Li T. C., Laird S. M. Expression of leukaemia inhibitory factor and interleukin 15 in endometrium of women with recurrent implantation failure after IVF; correlation with the number of endometrial natural killer cells // Human reproduction. - 2012. - Vol. 27. 122 7. - P. 1946-1954. 146. MasCasullo V., Fam E., Keller M. J., Herold B. C. Role of mucosal immunity in preventing genital herpes infection // Viral immunology. - 2005. Vol. 18. - 4. - P. 595-606. 147. Mashburn J. Etiology, diagnosis, and management of vaginitis // Journal of midwifery & women's health. - 2006. - Vol. 51. - 6. - P. 423-430. 148. Mege J. L., Mehraj V., Capo C. Macrophage polarization and bacterial infections // Current opinion in infectious diseases. - 2011. - Vol. 24. - 3. - P. 230-234. 149. Mirmonsef P., Gilbert D., Zariffard M. R., Hamaker B. R., Kaur A., Landay A. L., Spear G. T. The effects of commensal bacteria on innate immune responses in the female genital tract // American journal of reproductive immunology. 2011. - Vol. 65. - 3. - P. 190-195. 150. Mitchell C., Manhart L. E., Thomas K., Fiedler T., Fredricks D. N., Marrazzo J. Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study // Infectious diseases in obstetrics and gynecology. - 2012. - Vol. 2012. - P. 706540. 151. Mitchell C. M., Balkus J., Agnew K. J., Cohn S., Luque A., Lawler R., Coombs R. W., Hitti J. E. Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines // AIDS research and human retroviruses. - 2008. - Vol. 24. - 5. - P. 667-671. 152. Nasu K., Narahara H. Pattern recognition via the toll-like receptor system in the human female genital tract // Mediators of inflammation. - 2010. - Vol. 2010. - P. 976024. 153. Patel M. A., Nyirjesy P. Role of Mycoplasma and ureaplasma species in female lower genital tract infections // Current infectious disease reports. - 2010. Vol. 12. - 6. - P. 417-422. 154. Pejawar S. S., Parks G. D., Alexander-Miller M. A. Abortive versus productive viral infection of dendritic cells with a paramyxovirus results in differential upregulation of select costimulatory molecules // Journal of virology. - 2005. - Vol. 79. - 12. - P. 7544-7557. 123 155. Philpott D. J., Girardin S. E. The role of Toll-like receptors and Nod proteins in bacterial infection // Molecular immunology. - 2004. - Vol. 41. - 11. - P. 1099-1108. 156. Piccinni M. P. T cells in normal pregnancy and recurrent pregnancy loss // Reproductive biomedicine online. - 2006. - Vol. 13. - 6. - P. 840-844. 157. Pivarcsi A., Bodai L., Rethi B., Kenderessy-Szabo A., Koreck A., Szell M., Beer Z., Bata-Csorgoo Z., Magocsi M., Rajnavolgyi E., Dobozy A., Kemeny L. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes // International immunology. - 2003. - Vol. 15. - 6. - P. 721-730. 158. Pudney J., Quayle A. J., Anderson D. J. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone // Biology of reproduction. - 2005. - Vol. 73. 6. - P. 1253-1263. 159. Quan M. Vaginitis: diagnosis and management // Postgraduate medicine. 2010. - Vol. 122. - 6. - P. 117-127. 160. Quayle A. J. The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells // Journal of reproductive immunology. - 2002. - Vol. 57. - 1-2. - P. 61-79. 161. Raska M., Belakova J., Krupka M., Weigl E. Candidiasis--do we need to fight or to tolerate the Candida fungus? // Folia microbiologica. - 2007. - Vol. 52. - 3. - P. 297-312. 162. Ravel J., Gajer P., Abdo Z., Schneider G. M., Koenig S. S., McCulle S. L., Karlebach S., Gorle R., Russell J., Tacket C. O., Brotman R. M., Davis C. C., Ault K., Peralta L., Forney L. J. Vaginal microbiome of reproductive-age women // Proceedings of the National Academy of Sciences of the United States of America. - 2011. - Vol. 108 Suppl 1. - P. 4680-4687. 163. Roeder A., Kirschning C. J., Rupec R. A., Schaller M., Korting H. C. Tolllike receptors and innate antifungal responses // Trends in microbiology. - 2004. Vol. 12. - 1. - P. 44-49. 164. Romero R., Chaiworapongsa T., Kuivaniemi H., Tromp G. Bacterial vaginosis, the inflammatory response and the risk of preterm birth: a role for 124 genetic epidemiology in the prevention of preterm birth // American journal of obstetrics and gynecology. - 2004. - Vol. 190. - 6. - P. 1509-1519. 165. Rydstrom A., Wick M. J. Monocyte recruitment, activation, and function in the gut-associated lymphoid tissue during oral Salmonella infection // Journal of immunology. - 2007. - Vol. 178. - 9. - P. 5789-5801. 166. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance // Cell. - 2008. - Vol. 133. - 5. - P. 775-787. 167. Say P. J., Jacyntho C. Difficult-to-manage vaginitis // Clinical obstetrics and gynecology. - 2005. - Vol. 48. - 4. - P. 753-768. 168. Schellenberg J. J., Plummer F. A. The Microbiological Context of HIV Resistance: Vaginal Microbiota and Mucosal Inflammation at the Viral Point of Entry // International journal of inflammation. - 2012. - Vol. 2012. - P. 131243. 169. Schwiertz A., Taras D., Rusch K., Rusch V. Throwing the dice for the diagnosis of vaginal complaints? // Annals of clinical microbiology and antimicrobials. - 2006. - Vol. 5. - P. 4. 170. Sherrard J., Donders G., White D., Jensen J. S. European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011 // International journal of STD & AIDS. - 2011. - Vol. 22. - 8. - P. 421-429. 171. Spear G. T., St John E., Zariffard M. R. Bacterial vaginosis and human immunodeficiency virus infection // AIDS research and therapy. - 2007. - Vol. 4. - P. 25. 172. St John E. P., Martinson J., Simoes J. A., Landay A. L., Spear G. T. Dendritic cell activation and maturation induced by mucosal fluid from women with bacterial vaginosis // Clinical immunology. - 2007. - Vol. 125. - 1. - P. 95- 102. 173. Stevens A., Lowe J. S. Human histology. /. - Philadelphia: Elsevier Mosby, 2005.: - 464 . 174. Strober W. Epithelial cells pay a Toll for protection // Nature medicine. 2004. - Vol. 10. - 9. - P. 898-900. 125 175. Strobl H., Knapp W. Myeloid cell-associated lysosomal proteins as flow cytometry markers for leukocyte lineage classification // Journal of biological regulators and homeostatic agents. - 2004. - Vol. 18. - 3-4. - P. 335-339. 176. Tchilian E. Z., Beverley P. C. Altered CD45 expression and disease // Trends in immunology. - 2006. - Vol. 27. - 3. - P. 146-153. 177. Tempera G., Furneri P. M. Management of aerobic vaginitis // Gynecologic and obstetric investigation. - 2010. - Vol. 70. - 4. - P. 244-249. 178. Tezuka H., Abe Y., Iwata M., Takeuchi H., Ishikawa H., Matsushita M., Shiohara T., Akira S., Ohteki T. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells // Nature. - 2007. - Vol. 448. 7156. - P. 929-933. 179. Thoma-Uszynski S., Kiertscher S. M., Ochoa M. T., Bouis D. A., Norgard M. V., Miyake K., Godowski P. J., Roth M. D., Modlin R. L. Activation of tolllike receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10 // Journal of immunology. - 2000. - Vol. 165. - 7. - P. 3804-3810. 180. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity // Nature reviews. Immunology. - 2003. - Vol. 3. - 2. - P. 133-146. 181. Underhill D. M. Toll-like receptors and microbes take aim at each other // Current opinion in immunology. - 2004. - Vol. 16. - 4. - P. 483-487. 182. Valore E. V., Wiley D. J., Ganz T. Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis // Infection and immunity. - 2006. - Vol. 74. 10. - P. 5693-5702. 183. van de Veerdonk F. L., Gresnigt M. S., Kullberg B. J., van der Meer J. W., Joosten L. A., Netea M. G. Th17 responses and host defense against microorganisms: an overview // BMB reports. - 2009. - Vol. 42. - 12. - P. 776- 787. 184. van de Veerdonk F. L., Kullberg B. J., van der Meer J. W., Gow N. A., Netea M. G. Host-microbe interactions: innate pattern recognition of fungal pathogens // Current opinion in microbiology. - 2008. - Vol. 11. 312. 126 4. - P. 305- 185. Verhelst R., Verstraelen H., Claeys G., Verschraegen G., Delanghe J., Van Simaey L., De Ganck C., Temmerman M., Vaneechoutte M. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis // BMC microbiology. - 2004. - Vol. 4. - P. 16. 186. Verstraelen H., Verhelst R., Claeys G., Temmerman M., Vaneechoutte M. Culture-independent analysis of vaginal microflora: the unrecognized association of Atopobium vaginae with bacterial vaginosis // American journal of obstetrics and gynecology. - 2004. - Vol. 191. - 4. - P. 1130-1132. 187. Viscardi R. M. Ureaplasma species: role in diseases of prematurity // Clinics in perinatology. - 2010. - Vol. 37. - 2. - P. 393-409. 188. Wasiela M., Krzeminski Z., Kalinka J., Brzezinska-Blaszczyk E. [Correlation between levels of selected cytokines in cervico-vaginal fluid of women with abnormal vaginal bacterial flora] // Medycyna doswiadczalna i mikrobiologia. - 2005. - Vol. 57. - 3. - P. 327-333. 189. Weindl G., Naglik J. R., Kaesler S., Biedermann T., Hube B., Korting H. C., Schaller M. Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling // The Journal of clinical investigation. - 2007. - Vol. 117. - 12. - P. 3664-3672. 190. Witkin S. S., Linhares I. M., Giraldo P. Bacterial flora of the female genital tract: function and immune regulation // Best practice & research. Clinical obstetrics & gynaecology. - 2007. - Vol. 21. - 3. - P. 347-354. 191. Witkin S. S., Linhares I. M., Giraldo P., Ledger W. J. An altered immunity hypothesis for the development of symptomatic bacterial vaginosis // Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. - 2007. - Vol. 44. - 4. - P. 554-557. 192. Yamamoto M., Takeda K. Current views of toll-like receptor signaling pathways // Gastroenterology research and practice. - 2010. - Vol. 2010. - P. 240365. 127 193. Yamamoto T., Zhou X., Williams C. J., Hochwalt A., Forney L. J. Bacterial populations in the vaginas of healthy adolescent women // Journal of pediatric and adolescent gynecology. - 2009. - Vol. 22. - 1. - P. 11-18. 194. Yasodhara P., Raghunath M., Sreeramulu D., Venu L., Hemalatha R., Krishna T. P. Local immunity in Indian women with bacterial vaginosis // Journal of reproductive immunology. - 2006. - Vol. 70. - 1-2. - P. 133-141. 195. Zhang D., Liu Z. H., Liao Q. P., Ma J. M., Sun Y. F., Fan S. R., Hu L. N., Jia H. J., Di W., Wang W. [Study of local immunity of lower genital tract infections] // Zhonghua fu chan ke za zhi. - 2009. - Vol. 44. - 1. - P. 13-15. 196. Zhou X., Bent S. J., Schneider M. G. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods // Microbiology. - 2004. - Vol. 150. - 8. - P. 2565-2573. 197. Zhou X., Westman R., Hickey R., Hansmann M. A., Kennedy C., Osborn T. W., Forney L. J. Vaginal microbiota of women with frequent vulvovaginal candidiasis // Infection and immunity. - 2009. - Vol. 77. - 128 9. - P. 4130-4135.